Credit Suisse’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Credit Suisse’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$649K	Sell	18,561 -1,181	-6%	-$43.1K	﹤0.01%	2514
2023 Q4	$750K	Sell	19,742 -3,167	-14%	-$67.9K	﹤0.01%	2522
2023 Q3	$420K	Sell	22,909 -6,494	-22%	-$136K	﹤0.01%	2769
2023 Q2	$763K	Buy	29,403 +9,013	+44%	+$210K	﹤0.01%	2566
2023 Q1	$385K	Buy	20,390 +1,274	+7%	+$29.6K	﹤0.01%	2886
2022 Q4	$471K	Sell	19,116 -810	-4%	-$23.8K	﹤0.01%	2825
2022 Q3	$358K	Buy	19,926 +7,966	+67%	+$144K	﹤0.01%	2994
2022 Q2	$136K	Buy	+11,960	New	+$176K	﹤0.01%	3457
2022 Q1	–	Sell	-7,220	Closed	-$315K	–	4580
2021 Q4	$315K	Buy	+7,220	New	+$289K	﹤0.01%	4104

Other funds holding INBX

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Credit Suisse's INBX Position: Q1 2024 in Review

Credit Suisse reduced its Inhibrx, Inc. Common Stock (INBX) stake by 6% in Q1 2024, selling an estimated $43.1K and leaving 18,561 shares worth $649K. The position accounts for ﹤0.01% of the portfolio, ranked #2514.

Credit Suisse first reported a position in INBX in Q4 2021 and has held it in 9 quarters since. The position peaked at $763K in Q2 2023. 126 funds tracked by Wall St. Rank hold INBX as of Q1 2024.

Credit Suisse held 18,561 shares of Inhibrx, Inc. Common Stock worth $649K as of Q1 2024.
Credit Suisse sold 1,181 Inhibrx, Inc. Common Stock shares in Q1 2024, an estimated $43.1K.
Inhibrx, Inc. Common Stock made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2514 holding.
Credit Suisse first reported a position in Inhibrx, Inc. Common Stock in Q4 2021 and has held it in 9 quarters since.
Credit Suisse's Inhibrx, Inc. Common Stock position peaked at $763K in Q2 2023.
126 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.